Physician profile
Brian E Snell
NPI 1225021702
$3,728,570.17
in general payments reported to CMS, 2019-2025
8 companies · $164K in 2025
The $164K reported for 2025 was more than what 99% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $73.76 · 2021: $1.2M · 2022: $1.2M · 2023: $891K · 2024: $297K · 2025: $164K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $1.2M · Royalty Or License: $120K · Consulting Fee: $44K · Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $1,188,000.00 |
| Royalty Or License | $120,000.00 |
| Consulting Fee | $44,000.00 |
| Food and Beverage | $188.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omnia Medical, LLC | $3,728,000.00 | 2021-2025 | |
| Medtronic USA, INC. | $190.06 | 2019-2020 | |
| Kerecis Limited | $148.10 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Aesculap Implant Systems, LLC | $117.61 | 2019 | |
| Medtronic, INC. | $58.02 | 2021 | |
| Biotronik INC. | $25.21 | 2025 | |
| Allergan, INC. | $16.01 | 2020 | |
| Abbvie INC. | $15.16 | 2023 | Botox |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Snell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.